Why Novo Nordisk’s Weight Loss Pill Has Taken Off
Novo Nordisk's weight loss pill is expanding the obesity treatment market as an alternative to injectable GLP-1 medications. CNBC spoke ...
Tuesday, April 7, 2026
Tag: GLP-1
Novo Nordisk CSO on New Obesity Shot Results and Drug Pipeline
Novo Nordisk Chief Scientific Officer Martin Holst Lange discusses the recent clinical trial results of the company's weight loss obesity ...
An Obesity shot from Eli Lilly helped some people lose 23% of body weight
A next-generation obesity shot from Eli Lilly helped patients lose nearly a quarter of their body weight, potentially making the ...
Nasdaq notches fresh record high, how to play the GLP-1 pharma space
The S&P 500 and the Dow Jones Industrial Average both closed higher on Friday, with the Nasdaq Composite notching a ...
How Eli Lilly and Novo Nordisk have separated themselves from their rivals
Most companies are likely going to feel the impact of President Trump's tariffs. In the video above, BofA Securities senior ...
Why Eli Lilly is a top GLP-1 stock: Roundhill CEO
Pharmaceutical companies have significantly grown over the last year as demand for GLP-1 weight-loss drugs continues to skyrocket. Roundhill Investments ...
Stay updated with DeFi Daily, your trusted source for the latest news, insights, and analysis in finance and cryptocurrency. Explore breaking news, expert analysis, market data, and educational resources to navigate the world of decentralized finance.